Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG1205 DDI study with CYP450 substrates
NCT02623296Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Oct 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GLPG1205 in idiopathic pulmonary fibrosis (IPF), sponsored by Galapagos NV. Started Oct 2015; status: completed.
02
Drugs
GLPG1205
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02623296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02623296.